Bernie Boylan

MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD.

Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA.

Adheron Therapeutics, Inc. discovers and develops therapeutic drugs. The firm offers Cadherin-11 antagonists for the treatment of rheumatoid arthritis and fibrotic diseases including pulmonary fibrosis and skin fibrosis. The company was founded by David Lee, Michael B. Brenner, and David L. Castaldi in 2006 and is headquartered in Berkeley, CA.

PharmaKodex Ltd. develops pharmaceuticals products. It uses oral and transdermal drug delivery technologies to develop improved medicinal products. It develops and commercializes its products and technologies in an overlapping two component process. The company was founded in 2005 and is headquartered in Chippenham, UK

AbCellera Boston, Inc. produces vaccines for plant, animal, and human diseases. It focuses on the discovery of novel therapeutics for autoimmune disease and pain. The company was founded by Theodore G. Clark in 2004 and is headquartered in Arlington, MA.

Zyngenia, Inc. developed new class of bio-therapeutics. The company was founded by Joseph L. Amprey III, Carlos F. Barbas III and Peter Alec Kiener in 2008 and headquartered in Gaithersburg, MD.

The University of Liverpool operates as a university. It offers post graduate research, foundation courses, continuing and professional development, online study, and doctoral college. The company was founded in 1881 and is headquartered in Liverpool, the United Kingdom.

Part of Dassault Systèmes SA, Cambridge Combinatorial Ltd. is a company engaged in the design, production and supply of compounds for the pharmaceutical industry. The company is based in Cambridge, UK. Cambridge Combinatorial was acquired by Oxford Molecular Group Plc on October 15, 1998 for $20.78 million. The British company was founded by Allan P. Marchington.

Part of Signature BioScience, Inc., Cambridge Discovery Chemistry provides chemistry research services. Cambridge Discovery Chemistry was acquired by Signature BioScience, Inc. from Millennium Pharmaceuticals, Inc. on July 16, 2001.

The BioIndustry Association is a UK-based organization that represents the life sciences and biotech industry. The British company's mission is to facilitate and connect the ecosystem to help businesses start, grow, and deliver world-changing innovation. The non-profit company was founded by Cormac G. Kilty and Simon Geoffrey Best, and Steve Bates has been the CEO of the company since 2012.

Bird Rock Bio, Inc. develops protein therapeutics. It focuses on the discovery and development of novel antibodies with upsized potential that represent to antibody therapeutics. The company was founded by Richard J. Ulevitch, Phyllis Ellen Whiteley and Katherine S. Bowdish in 2007 and is headquartered in La Jolla, CA.

Intermediate Capital Group Plc (Private Equity) (ICG) is a private equity division of Intermediate Capital Group Plc founded in 1989. The firm is headquartered in London, United Kingdom.

Kuur Therapeutics provides clinical cellular therapeutics services. It develops, manufactures and markets personalized cellular immunotherapeutics for infectious disease and cancer. Cell Medica has developed proprietary production technology enabling GMP compliant manufacture of antigen-specific T cells. The company was founded by Gregg Sando in 2006 and is headquartered in London, the United Kingdom.

Resolve Therapeutics LLC operates as a biotechnology company. It engages in the development of biotechnology drugs. The firm specializes in treatment of debilitating autoimmune diseases such as Systemic Lupus Erythematous and Sjogren’s syndrome. The company was founded by James Posada in 2010 and is headquartered in Seattle, WA.

Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom.

Cereius, Inc. develops novel radio-labeled therapeutics for treating solid tumor brain metastasis. The firm delivers new targeted classes of both radiologic diagnostics and radiotherapeutics for the treatment of cancers in the brain. The company was founded by Kimberly Blackwell and Michael R. Zalutsky in 2017 and is headquartered in Durham, NC.

Wugen, Inc. develops CAR-T therapy platform for cancer therapies. The company was founded by Matthew Cooper and John F. DiPersio and is headquartered in St. Louis, MO.

Itolerance, Inc. is an American biotechnology company that specializes in developing regenerative medicines. The private company was founded by Cameron Gray and is currently led by CEO Anthony J. Japour.